Immuneering Corp Stock In The News

IMRX Stock  USD 2.13  0.11  5.45%   
Our overall analysis of Immuneering Corp's news coverage and content from conventional and social sources shows investors' bearish mood towards Immuneering Corp. The specific impact of Immuneering Corp news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Immuneering Corp's overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Immuneering Corp headlines in addition to utilizing other, more conventional financial analysis modules. Check out Immuneering Corp Backtesting and Immuneering Corp Hype Analysis.
For more information on how to buy Immuneering Stock please use our How to Invest in Immuneering Corp guide.

Immuneering Corp Today Top News and Investor Outlook

Yahoo News
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?
https://finance.yahoo.com/news/why-amicus-immunocore-immuneering-stocks-191050213.html
 Neutral
Macroaxis News: globenewswire.com
Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference
https://www.globenewswire.com/news-release/2023/11/20/2783587/0/en/Immuneering-to-Present-at-the-35th-Annual-Piper-Sandler-Healthcare-Conference.html
 Neutral
Macroaxis News: globenewswire.com
SHAREHOLDER ALERT: Kaskela Law LLC Annou...
https://www.globenewswire.com/news-release/2023/11/11/2778582/0/en/SHAREHOLDER-ALERT-Kaskela-Law-LLC-Announces-Investigation-of-Immuneering-Corporation-NASDAQ-IMRX-and-Encourages-Investors-to-Contact-the-Firm.html
 Bullish
Macroaxis News: globenewswire.com
Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates
https://www.globenewswire.com/news-release/2023/11/09/2777808/0/en/Immuneering-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Business-Updates.html
 Neutral
Macroaxis News: globenewswire.com
Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference
https://www.globenewswire.com/news-release/2023/10/12/2759646/0/en/Immuneering-Presents-Preclinical-Data-Demonstrating-Encouraging-Anti-Tumor-Activity-for-IMM-1-104-and-IMM-6-415-at-AACR-NCI-EORTC-Conference.html
 Neutral
Macroaxis News: globenewswire.com
Immuneering to Present Preclinical Data ...
https://www.globenewswire.com/news-release/2023/10/04/2754930/0/en/Immuneering-to-Present-Preclinical-Data-on-IMM-1-104-and-IMM-6-415-at-AACR-NCI-EORTC-International-Conference-on-Molecular-Targets-and-Cancer-Therapeutics.html
 Neutral
Macroaxis News: globenewswire.com
Immuneering to Present at the Morgan Stanley Healthcare Conference
https://www.globenewswire.com/news-release/2023/09/06/2738329/0/en/Immuneering-to-Present-at-the-Morgan-Stanley-Healthcare-Conference.html
 Neutral
Macroaxis News: globenewswire.com
Immuneering Reports Second Quarter 2023 Financial Results and Provides Business Updates
https://www.globenewswire.com/news-release/2023/08/03/2718562/0/en/Immuneering-Reports-Second-Quarter-2023-Financial-Results-and-Provides-Business-Updates.html
 Neutral
Macroaxis News: globenewswire.com
Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid Tumors
https://www.globenewswire.com/news-release/2023/06/05/2681894/0/en/Immuneering-Completes-Dose-Escalation-in-the-IMM-1-104-Phase-1-Clinical-Trial-for-RAS-Mutant-Advanced-Solid-Tumors.html
 Neutral
Macroaxis News: globenewswire.com
Immuneering to Present at the Jefferies Healthcare Conference
https://www.globenewswire.com/news-release/2023/05/30/2678271/0/en/Immuneering-to-Present-at-the-Jefferies-Healthcare-Conference.html
 Neutral

Immuneering Corp Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Immuneering and other traded companies coverage with news coverage. We help investors stay connected with Immuneering headlines for the 21st of January to make an informed investment decision based on correlating the impacts of news items on Immuneering Stock performance. Please note that trading solely based on the Immuneering Corp hype is not for everyone as timely availability and quick action are needed to avoid losses.
Immuneering Corp's linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Immuneering Corp investors visualize upcoming and past events in order to time the market based on Immuneering Corp noise-free hype analysis.
Immuneering Corp stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Immuneering earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Immuneering Corp that are available to investors today. That information is available publicly through Immuneering media outlets and privately through word of mouth or via Immuneering internal channels. However, regardless of the origin, that massive amount of Immuneering data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Immuneering Corp news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Immuneering Corp relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Immuneering Corp's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Immuneering Corp alpha.

Immuneering Largest EPS Surprises

Earnings surprises can significantly impact Immuneering Corp's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-03-01
2023-12-31-0.47-0.52-0.0510 
2024-08-07
2024-06-30-0.5267-0.470.056710 
2023-11-09
2023-09-30-0.49-0.430.0612 
2024-11-14
2024-09-30-0.5517-0.490.061711 
2023-03-06
2022-12-31-0.58-0.50.0813 
2022-08-10
2022-06-30-0.52-0.440.0815 
View All Earnings Estimates

Immuneering Corp Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Immuneering Corp Stock. Current markets are slightly bullish. About 55% of major world exchanges and indexes are currently up. See today's market update for more information.
Google News at Macroaxis
16th of January 2025
Immuneering Corporation Stock Soars Following Promising Updates from Phase 2a Pancreatic C...
at news.google.com 
Yahoo News
7th of January 2025
Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Ph...
at finance.yahoo.com 
Yahoo News
17th of December 2024
Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in ...
at finance.yahoo.com 
Gurufocus Stories at Macroaxis
27th of November 2024
Immuneering to Present at the Piper Sandler 36 Annual Healthcare Conference
at gurufocus.com 
Google News at Macroaxis
20th of November 2024
Immuneering Co. Given Consensus Recommendation of Moderate Buy by Brokerages - MarketBeat
at news.google.com 
Macroaxis News: globenewswire.com
13th of November 2024
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates
at globenewswire.com 

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Immuneering Corp in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Immuneering Corp's short interest history, or implied volatility extrapolated from Immuneering Corp options trading.

Additional Tools for Immuneering Stock Analysis

When running Immuneering Corp's price analysis, check to measure Immuneering Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immuneering Corp is operating at the current time. Most of Immuneering Corp's value examination focuses on studying past and present price action to predict the probability of Immuneering Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immuneering Corp's price. Additionally, you may evaluate how the addition of Immuneering Corp to your portfolios can decrease your overall portfolio volatility.